Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.32 |
| ▸ | ABAT | P80404 | 1/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30134282 | 1.00 | ERN1 (0.46) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL5291577 | 0.83 | ERN1 (0.50) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL15339919 | 0.82 | ERN1 (0.37) | ERN1CYP3A4MAPTTDP1ALDH1A1 | |
| SCHEMBL18873290 | 0.82 | ERN1 (0.47) | ERN1KDM4EPTGS2RAB9ATRIM24 | |
| SCHEMBL31351301 | 0.80 | ERN1 (0.49) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL7717189 | 0.80 | ERN1 (0.49) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL3975489 | 0.78 | ERN1 (0.43) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL415661 | 0.78 | ERN1 (0.42) | ERN1CYP3A4KDM4EPTGS2RAB9A | |
| SCHEMBL29950973 | 0.78 | ERN1 (0.43) | ERN1CYP3A4MAPTKDM4EPTGS2 | |
| SCHEMBL4650198 | 0.78 | CYP3A4 (0.44) | ERN1CYP3A4MAPTKDM4EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4543924-A2 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119744180-A | Human tumor necrosis factor alpha antibody glucocorticoid conjugate | 伊莱利利公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-119698436-A | Human CD33 antibodies and glucocorticoid conjugates | 伊莱利利公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4522222-A1 | HUMAN TUMOR NECROSIS FACTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | Eli Lilly and Company (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119630429-A | Human interleukin-4 receptor alpha antibody glucocorticoid conjugates | 伊莱利利公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4518906-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | Eli Lilly and Company (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240173425-A1 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240100176-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | ELI LILLY AND COMPANY | 2024-03-28 | — | — | US | disclosed |
| CN-117043172-A | Glucocorticoid receptor agonists | 伊莱利利公司 | 2023-11-10 | — | — | CN | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787834-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2023-07-20 | — | — | US | disclosed |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-10-13 | — | — | US | disclosed |
| WO-2022204108-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2022-09-29 | — | — | WO | disclosed |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2022-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173425-A1 | HUMAN CD33 ANTIBODIES AND GLUCOCORTICOID CONJUGATES | FCGR3B, FCGR1A, FCGR2A | ERN1 3730/4885CYP3A4 1139/4885MAPT 4258/4885 |
| US-20230227493-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | ERN1 2526/4885CYP3A4 985/4885MAPT 4721/4885 |
| US-20220306681-A1 | CARBOXY SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, MC2R, NR3C2 | ERN1 2526/4885CYP3A4 985/4885MAPT 4721/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-11787834-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20220324904-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | ERN1 1650/4885CYP3A4 911/4885MAPT 3892/4885 |
| US-20240100176-A1 | HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODY GLUCOCORTICOID CONJUGATES | IL4, IL2RA, IL2 | ERN1 4160/4885CYP3A4 226/4885MAPT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.